<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>7ec40822-f113-4565-bb88-bb1dee9a5f71</id>
  <name>COVID Casirivimab_Imdevimab Order Group</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]">
    <items>
      <item>
        <key>Transform.Technical Notes</key>
        <value>&lt;p&gt;Sept 7/21 - Pending author approval&lt;/p&gt;</value>
      </item>
    <item><key>Technical.ﻩ Technical Traceability</key><value>{~AHSID~7ec40822-f113-4565-bb88-bb1dee9a5f71~NAME~COVID Casirivimab_Imdevimab Order Group}</value></item></items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;p&gt;The AHS Criteria of use for casirivimab/imdevimab in COVID-19 &lt;strong&gt;inpatients&lt;/strong&gt; is as follows:&lt;/p&gt;&lt;p&gt;1. 4000/4000 mg dose restricted for the treatment of inpatients aged 12 or older weighing at least 40 kg hospitalized due to laboratory-confirmed COVID-19 who:&lt;/p&gt;&lt;p&gt;a.&amp;nbsp;&amp;nbsp;&amp;nbsp; Are eligible as follows:&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;i.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meet ALL of the following three criteria:&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Have no documented history of previous COVID-19 infection&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Have not previously received treatment with a COVID-19 neutralizing antibody (except bamlanivimab monotherapy)&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Have not received any doses of COVID-19 vaccine, unless fewer than 14 days have elapsed since receiving their first dose&lt;/p&gt;&lt;p&gt;&lt;strong&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; AND&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; ii.&amp;nbsp;&amp;nbsp;&amp;nbsp; Are seronegative according to the results of a COVID-19 lab-based or rapid serology test&lt;/p&gt;&lt;p&gt;&lt;strong&gt;OR&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;b.&amp;nbsp;&amp;nbsp;&amp;nbsp; Are immunocompromised, defined as follows:&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;- Congenital and acquired immunodeficiency including severe combined immunodeficiency (SCID) and profound hypogammaglobulinemia&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;- HIV infection with CD4 T lymphocyte count &amp;lt; 200 (or less than 15%) and unsuppressed viral load&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; ·&amp;nbsp;Pediatrics: 5 years or older – use CD4 count &amp;lt;200&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Any haemotological malignancy&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Within 24 months of stem cell transplant&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Solid organ transplant&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Current receipt of prednisone &amp;gt; 20 mg/day (or equivalent) for more than 14 days&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - For pediatrics: &amp;gt; 2mg/kg body weight for more than 14 days&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; -&amp;nbsp;Chimeric antigen receptor (CAR) T-cell therapy&lt;/p&gt;&lt;p&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; - Anti-B cell therapy (current or within last 6 months)&amp;nbsp;e.g. ocrelizumab, rituximab&lt;/p&gt;&lt;p&gt;2. 1200/1200 mg dose restricted to use in inpatients admitted for non-COVID reasons with nosocomial COVID-19 infection ONLY within the CATCO-NOS clinical trial.&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-INSTRUCTION.section_supporting_context.v1]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;N&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Consider if unvaccinated or immunocompromised - Casirivimab/Imdevimab (REGEN-COV)">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="fa80ca89-b938-4053-b4ab-6eaf57409b6f" concept_name="PLACEHOLDER Order Item" max="1" path="/items" name="PLACEHOLDER; casirivimab/imdevimab IV (COVID-19); *** mg, intravenous, once"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1">
    <digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1">
    <digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest>
  </integrity_checks>
</template>